Mark W. Surber, Ph.D.

Founder, President and Chief Executive Officer

Mark W. Surber, Ph.D. is a serial entrepreneur and founder of Genoa Pharmaceuticals. At Genoa, Dr. Surber serves as Chairman, President and Chief Executive Officer and is the inventor of the GP-101 patent estate. Dr. Surber has over 20 years of pharmaceutical, diagnostic and device development experience, most of which has been spent starting and growing pharmaceutical companies.

Prior to Genoa, Dr. Surber served as a consultant providing multi-disciplinary drug development services to pharmaceutical companies. These included Elevation Pharmaceuticals and Cardeas Pharma, both developing inhaled products. Prior to consulting, Dr. Surber was the first employee at Aires Pharmaceuticals (acquired by Mast Therapeutics in 2014) where he was project lead and an inventor of Aironite, an inhaled medicine for treatment of pulmonary hypertension. Dr. Surber was also and first employee at Mpex Pharmaceuticals (acquired by Aptalis Pharma in 2011) where he held multiple positions of responsibility including project lead and inventor of Aeroquin/Quinsair, an inhaled medicine approved for the treatment of cystic fibrosis. Dr. Surber is well-published and holds multiple patents in formulation, drug delivery, pharmacology and pulmonary medicine. He has a Ph.D. in microbiology from the University of Illinois, and a M.S. and B.Sc. in microbiology from California State University, Long Beach.

Richard G. Vincent

Co-Founder and Chief Financial Officer

Richard G. Vincent joined Genoa in June 2011 and serves as our Chief Financial Officer. Mr. Vincent previously held senior management positions at Meritage Pharma, Sorrento Therapeutics, Elevation Pharmaceuticals, Verus Pharmaceuticals, Women First HealthCare, Elan Pharmaceuticals, Phase Metrics, and Deloitte & Touche LLP, where he specialized in emerging growth and publicly-reporting companies. Over the past 20+ years, Mr. Vincent’s experience includes raising over $500 million through venture capital, major commercial banks and institutions, and public offering proceeds for high growth pharmaceutical and technology-based companies, and participating in a number of acquisitions and divestitures valued at over $1 billion. Mr. Vincent was named 2014 public company CFO of the Year in San Diego by the San Diego Business Journal. Mr. Vincent became a Certified Public Accountant in California and holds a B.S. degree in business from San Diego State University.